Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 22 Oct, 19:27 UTC

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction,” one analyst wrote.

science

Sources

• T2Moderna, Merck shares fall on eagerly anticipated cancer vaccine resultsBioPharma Dive / Healthcare Dive / MedTech Dive22 Oct, 19:27